Telix Pharmaceuticals Ltd Files H1 2025 Results
Ticker: TLPPF · Form: 6-K · Filed: Aug 21, 2025 · CIK: 2007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLPPF) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: results, financial-reporting, foreign-issuer
TL;DR
Telix Pharma dropped its H1 2025 results, check the 6-K.
AI Summary
On August 21, 2025, Telix Pharmaceuticals Limited announced its H1 2025 results, including a presentation, Appendix 4D, and interim report. The company is a foreign private issuer filing a Form 6-K with the SEC.
Why It Matters
This filing provides investors with the latest financial and operational performance data for Telix Pharmaceuticals Ltd for the first half of 2025.
Risk Assessment
Risk Level: low — This is a routine financial results filing for a publicly traded company.
Key Players & Entities
- Telix Pharmaceuticals Limited (company) — Filer of the report
- August 21, 2025 (date) — Date of filing announcements
- Australian Securities Exchange (company) — Exchange where announcements were made
- H1 2025 (period) — Reporting period for the results
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed by Telix Pharmaceuticals Limited to report its H1 2025 results, including a presentation, Appendix 4D, and interim report, to the U.S. Securities and Exchange Commission.
When were the H1 2025 results announced?
The H1 2025 results were announced on August 21, 2025.
Where are Telix Pharmaceuticals Limited's principal executive offices located?
Telix Pharmaceuticals Limited's principal executive offices are located at 55 Flemington Road, North Melbourne, Victoria 3051, Australia.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934.
Does Telix Pharmaceuticals Limited file annual reports under Form 20-F or 40-F?
Telix Pharmaceuticals Limited indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2025-08-20 20:39:59
Filing Documents
- halfyr6k.htm (6-K) — 11KB
- prez.htm (EX-99.1) — 2KB
- report.htm (EX-99.2) — 3KB
- results.htm (EX-99.3) — 0KB
- prez1.jpg (GRAPHIC) — 130KB
- prez2.jpg (GRAPHIC) — 460KB
- prez3.jpg (GRAPHIC) — 144KB
- prez4.jpg (GRAPHIC) — 157KB
- prez5.jpg (GRAPHIC) — 212KB
- prez6.jpg (GRAPHIC) — 278KB
- prez7.jpg (GRAPHIC) — 114KB
- prez8.jpg (GRAPHIC) — 257KB
- prez9.jpg (GRAPHIC) — 172KB
- prez10.jpg (GRAPHIC) — 239KB
- prez11.jpg (GRAPHIC) — 218KB
- prez12.jpg (GRAPHIC) — 264KB
- prez13.jpg (GRAPHIC) — 130KB
- prez14.jpg (GRAPHIC) — 225KB
- prez15.jpg (GRAPHIC) — 145KB
- prez16.jpg (GRAPHIC) — 127KB
- prez17.jpg (GRAPHIC) — 178KB
- prez18.jpg (GRAPHIC) — 236KB
- prez19.jpg (GRAPHIC) — 209KB
- prez20.jpg (GRAPHIC) — 228KB
- prez21.jpg (GRAPHIC) — 227KB
- prez22.jpg (GRAPHIC) — 207KB
- prez23.jpg (GRAPHIC) — 113KB
- prez24.jpg (GRAPHIC) — 200KB
- prez25.jpg (GRAPHIC) — 128KB
- prez26.jpg (GRAPHIC) — 203KB
- prez27.jpg (GRAPHIC) — 195KB
- prez28.jpg (GRAPHIC) — 197KB
- prez29.jpg (GRAPHIC) — 217KB
- prez30.jpg (GRAPHIC) — 217KB
- prez31.jpg (GRAPHIC) — 143KB
- prez32.jpg (GRAPHIC) — 184KB
- prez33.jpg (GRAPHIC) — 220KB
- prez34.jpg (GRAPHIC) — 265KB
- prez35.jpg (GRAPHIC) — 235KB
- prez36.jpg (GRAPHIC) — 230KB
- prez37.jpg (GRAPHIC) — 222KB
- prez38.jpg (GRAPHIC) — 206KB
- report1.jpg (GRAPHIC) — 166KB
- report2.jpg (GRAPHIC) — 205KB
- report3.jpg (GRAPHIC) — 111KB
- report4.jpg (GRAPHIC) — 69KB
- report5.jpg (GRAPHIC) — 259KB
- report6.jpg (GRAPHIC) — 166KB
- report7.jpg (GRAPHIC) — 218KB
- report8.jpg (GRAPHIC) — 191KB
- report9.jpg (GRAPHIC) — 253KB
- report10.jpg (GRAPHIC) — 288KB
- report11.jpg (GRAPHIC) — 256KB
- report12.jpg (GRAPHIC) — 210KB
- report13.jpg (GRAPHIC) — 212KB
- report14.jpg (GRAPHIC) — 308KB
- report15.jpg (GRAPHIC) — 70KB
- report16.jpg (GRAPHIC) — 117KB
- report17.jpg (GRAPHIC) — 71KB
- report18.jpg (GRAPHIC) — 133KB
- report19.jpg (GRAPHIC) — 243KB
- report20.jpg (GRAPHIC) — 264KB
- report21.jpg (GRAPHIC) — 227KB
- report22.jpg (GRAPHIC) — 205KB
- report23.jpg (GRAPHIC) — 377KB
- report24.jpg (GRAPHIC) — 312KB
- report25.jpg (GRAPHIC) — 300KB
- report26.jpg (GRAPHIC) — 266KB
- report27.jpg (GRAPHIC) — 188KB
- report28.jpg (GRAPHIC) — 219KB
- report29.jpg (GRAPHIC) — 188KB
- report30.jpg (GRAPHIC) — 171KB
- report31.jpg (GRAPHIC) — 200KB
- report32.jpg (GRAPHIC) — 203KB
- report33.jpg (GRAPHIC) — 169KB
- report34.jpg (GRAPHIC) — 213KB
- report35.jpg (GRAPHIC) — 260KB
- report36.jpg (GRAPHIC) — 236KB
- report37.jpg (GRAPHIC) — 335KB
- report38.jpg (GRAPHIC) — 314KB
- report39.jpg (GRAPHIC) — 191KB
- report40.jpg (GRAPHIC) — 105KB
- report41.jpg (GRAPHIC) — 151KB
- report42.jpg (GRAPHIC) — 269KB
- report43.jpg (GRAPHIC) — 220KB
- report44.jpg (GRAPHIC) — 278KB
- report45.jpg (GRAPHIC) — 286KB
- report46.jpg (GRAPHIC) — 159KB
- report47.jpg (GRAPHIC) — 125KB
- report48.jpg (GRAPHIC) — 233KB
- report49.jpg (GRAPHIC) — 215KB
- report50.jpg (GRAPHIC) — 174KB
- report51.jpg (GRAPHIC) — 247KB
- report52.jpg (GRAPHIC) — 208KB
- report53.jpg (GRAPHIC) — 131KB
- results1.jpg (GRAPHIC) — 273KB
- results2.jpg (GRAPHIC) — 289KB
- results3.jpg (GRAPHIC) — 305KB
- results4.jpg (GRAPHIC) — 375KB
- 0002007191-25-000063.txt ( ) — 27781KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Telix Pharmaceuticals Limited       Date: August 21, 2025 By: /s/ Genevieve Ryan     Name: Genevieve Ryan     Title: Company Secretary